Legend Biotech has tapped Novartis executive Ingrid Zhang as its new CEO at a time when the company is seeking its next act.

PA­LO AL­TO, CA — Af­ter giv­ing ar­ti­fi­cial in­tel­li­gence tools to thou­sands of em­ploy­ees, Bris­tol My­ers Squibb is now work­ing to get a han­dle on the costs of the tech­nol­o­gy and where ...

Welcome back to another edition of Endpoints Weekly! We’ll get to the headlines in just a bit, but be sure to check out the ...

Gilead expands lenacapavir HIV PrEP access in Latin America; Cloudbreak IPO probed; Sironax gets $125M from Novartis; Circle ...

Endpoints takes its China biotech debate to DC: four Post-Hoc Live conversations on patents, FDA data, biosecurity and ...

CMS signaled drugmakers joining its Generous Medicaid rebate demo would be exempt from the Globe and Guard Medicare pilots, ...

CART01; Ori bags $120M deal; Reckitt invests $600M in US; Astellas expands Ireland; Hovione opens NJ facility.

Six UK parliamentary committees ask the National Audit Office to probe the cost of the £1B UK-US pharma deal and its NHS ...

FDA grants accelerated approval to Ultragenyx's Sanfilippo gene therapy UX111, weeks after the biotech's Angelman Phase 3 ...

An extended-release version of deucrictibant reduced patients’ mean monthly attack rate by 83% compared to placebo, meeting ...

The FDA ap­proved a new com­bi­na­tion reg­i­men from Eli Lil­ly for cer­tain breast can­cer pa­tients, a reg­i­men that in­cludes Lil­ly’s oral se­lec­tive es­tro­gen re­cep­tor de­grad­er (SERD) ...

In­vestors are pump­ing $123 mil­lion in­to a tiny Michi­gan biotech that is res­ur­rect­ing an Astel­las can­cer drug for an eye dis­ease that has at­tract­ed lots of VC and phar­ma at­ten­tion in ...